Why the study?
To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy.
Do myosin inhibitors improve exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy?
Do myosin inhibitors improve exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy?
This is a protocol for a Cochrane Review to assess the efficacy and safety of myosin inhibitors in patients with hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Protocol for myosin inhibitor review in HCM leaves efficacy and safety questions open; signals forthcoming high-level evidence synthesis.
OBJECTIVES: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: Primary objective To assess the effects of myosin inhibitors compared to usual care or placebo on exercise capacity, need for septal reduction therapy, and all-cause mortality in people with hypertrophic cardiomyopathy (HCM). Secondary objectives To assess the effects of myosin inhibitors compared to usual care or placebo in people with HCM in the following population subgroups. By demographics, such as age and sex Obstructive HCM versus non-obstructive HCM Genotype-negative and genotype-positive disease People with and without pre-existing atrial fibrillation or other types of arrhythmias.
No takes yet. Share an insight, caveat, or question.
Quill et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: